NLNK - NewLink Genetics Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

NewLink Genetics Corporation

2503 South Loop Drive
Suite 5100
Ames, IA 50010
United States

Full Time Employees55

Key Executives

NameTitlePayExercisedYear Born
Dr. Eugene P. Kennedy M.D., FACSChief Medical Officer619.64kN/A1969
Mr. Carl W. LangrenCFO & Principal Accounting OfficerN/AN/A1955
Ms. Lisa MillerDirector of Investor RelationsN/AN/AN/A
Brad J. PowersGen. CounselN/AN/AN/A
Mr. Mario Mautino Ph.D.Sr. VP of Drug Discovery & Intellectual Property OfficerN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Corporate Governance

NewLink Genetics Corporation’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.